Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;57(7):1590-1599.
doi: 10.1002/ppul.25948. Epub 2022 May 27.

Cystic fibrosis year in review 2021

Adrienne P Savant  1   2
Affiliations
Review

Cystic fibrosis year in review 2021

Adrienne P Savant. Pediatr Pulmonol. 2022 Jul.

Abstract

People with cystic fibrosis (CF) have an amazing outlook with the treatment availability of highly effective modulators. Unfortunately, not all people with CF are eligible for modulators leading to continued pulmonary exacerbations and advanced lung disease. Additionally, optimizing diagnosis and evaluation for CF in the newborn period continues to be an area of focus for research. This review article will work to cover articles published in 2021 with high clinical relevance related to the above topics; however, due to the extensive body of research published, this review will not be comprehensive.

Keywords: CFTR modulators; advanced lung disease; cystic fibrosis; newborn screening; pulmonary exacerbations.

PubMed Disclaimer

References

REFERENCES

    1. Davies JC, Wainwright CE, Sawicki GS, et al. Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation. Results of a two-part phase 3 clinical trial. Am J Respir Crit Care Med. 2021;203(5):585-593.
    1. Kerem E, Cohen-Cymberknoh M, Tsabari R, et al. Ivacaftor in people with cystic fibrosis and a 3849+10kb C-->T or D1152H residual function mutation. Ann Am Thorac Soc. 2021;18(3):433-441.
    1. cftr2.org. Accessed 11 April, 2022. https://cftr2.org/
    1. Kawala CR, Ma X, Sykes J, Stanojevic S, Coriati A, Stephenson AL. Real-world use of ivacaftor in Canada: a retrospective analysis using the Canadian Cystic Fibrosis Registry. J Cyst Fibros. 2021;20(6):1040-1045.
    1. Mitchell RM, Jones AM, Stocking K, Foden P, Barry PJ. Longitudinal effects of ivacaftor and medicine possession ratio in people with the Gly551Asp mutation: a 5-year study. Thorax. 2021;76(9):874-879.

Substances